Phase 2 Pulmonary Hypertension Trial, Recruiting NCT06104228 Sponsor: Bastiaan Driehuys Condition: Pulmonary Hypertension
Back to Pulmonary Hypertension

Phase 2 Pulmonary Hypertension Trial, Recruiting

NCT06104228
Recruiting Phase 2

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

For Arm 1 (Idiopathic Pulmonary Arterial Hypertension – IPAH):

  • You are between 18 and 75 years old
  • Your pulmonary arterial hypertension (high blood pressure in the lungs) affects your daily activities at a moderate level (confirm with trial site for exact classification)
  • Your lung artery pressure measurements meet specific levels shown by a heart catheter test (confirm with trial site)
  • No other medical reason has been found to explain your high lung blood pressure

For Arm 2 (PAH linked to Connective Tissue Disease – PAH-CTD):

  • You are between 18 and 75 years old
  • Your pulmonary arterial hypertension affects your daily activities at a moderate level (confirm with trial site for exact classification)
  • Your lung artery pressure measurements meet specific levels shown by a heart catheter test (confirm with trial site)
  • You have been diagnosed with a connective tissue disease (such as lupus, scleroderma, or a similar condition)

Who may not be able to join:

  • You have high blood pressure in the lungs caused by something other than idiopathic PAH or PAH linked to connective tissue disease
  • You have any condition that would prevent you from safely having a special type of lung MRI scan using inhaled xenon gas (confirm with trial site)

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 26 July 2026
Phase 2: approximately ~30% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.
Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

Contact this trial

Principal Investigator: Fawaz Alenezi, MD, Duke Univeristy

Phone: +1 919 660 2026

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Phase 2
Sponsor
Bastiaan Driehuys
Registry
ClinicalTrials.gov
Start date
12 August 2024
Est. completion
1 January 2027

Where this trial is recruiting

🇺🇸 United States

Primary endpoints

Pulmonary Vascular Remodeling

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 26 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov